Mode
Text Size
Log in / Sign up

EEG microstate duration and occurrence rates differ significantly between Alzheimer's patients and healthy controlsBrain wave patterns show differences in Alzheimer's and memory loss

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that EEG microstate parameters differ in AD and MCI but currently lack sufficient certainty for clinical diagnosis.

This meta-analysis synthesized data from 16 studies to evaluate EEG microstate parameters—specifically duration and occurrence rate—in patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) compared to healthy controls. The analysis focused on identifying large-scale network dysfunction associated with these conditions.

The synthesis revealed that microstate A duration was significantly increased in AD patients (effect size 0.41; 95% CI [0.10, 0.72]) and microstate B duration was also significantly increased (effect size 0.48; 95% CI [0.23, 0.73]). In patients with MCI, the occurrence rate of microstate A was increased (effect size 0.40; 95% CI [0.07, 0.74]), while microstate D duration was significantly decreased (effect size -0.26; 95% CI [-0.48, -0.04]).

The authors noted substantial heterogeneity and possible small-study effects, which constrain the interpretation of these findings as clinical biomarkers. While EEG microstate analysis may provide complementary information regarding network dysfunction in MCI and AD, the current evidence is considered hypothesis-generating. Clinical utility for diagnosis remains uncertain due to methodological limitations.

How this fits prior evidence

This meta-analysis addresses a gap in identifying non-invasive markers of large-scale network dysfunction in Alzheimer's disease and mild cognitive impairment. While prior coverage has established high AUC for plasma p-tau217 and Aβ42/40 biomarkers to identify amyloid positivity, these EEG findings offer a different physiological perspective on neurodegeneration. The current evidence is hypothesis-generating rather than a confirmed diagnostic tool.

When someone faces Alzheimer's disease or mild cognitive impairment (MCI), their brain struggles to process and organize information. Researchers looked at EEG microstates, which are stable patterns of brain activity that help us understand how large networks in the brain function together.

The study analyzed 16 different reports involving people with these conditions compared to healthy individuals. They found that patients with Alzheimer's showed a significant increase in the duration of certain brain wave types (labeled A and B). Meanwhile, those with mild cognitive impairment showed an increased rate of occurrence for type A waves but a decrease in the duration of type D waves.

While these findings are helpful for understanding how the brain functions as it ages or declines, there is still a lot to learn. Because the data comes from many different studies, some results are less certain. For now, these patterns serve as a way to help scientists study brain networks rather than a tool for immediate diagnosis.

What this means for you:
Specific brain wave patterns change in people with Alzheimer's and mild memory loss.

Common questions

What are EEG microstates?

Microstates are stable patterns of electrical activity in the brain. They last for a very short time before switching to another state. Scientists study these patterns because they help show how large networks in the brain work together to process information.

How do these findings differ for Alzheimer's versus mild memory loss?

The study found that people with Alzheimer's had a significant increase in the duration of microstate A and B. For those with mild cognitive impairment, the results were different: they showed an increased occurrence rate of microstate A but a decrease in the duration of microstate D.

Can these brain waves be used to diagnose Alzheimer's?

Not yet. While these findings help researchers understand how brain networks fail, the evidence is currently used to generate new ideas for research. Because the data comes from many different sources, it is not yet a reliable tool for making a clinical diagnosis.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
OBJECTIVE: Electroencephalography (EEG) microstate analysis has emerged as a tool for investigating the spatial organization and temporal dynamics of large-scale cortical networks. Its potential role in identifying risk and progression of Alzheimer's dementia (AD) remains unclear. We conducted a systematic review and meta-analysis of EEG microstate parameters in AD and mild cognitive impairment (MCI). METHODS: PubMed, PsychINFO, EMBASE, and MEDLINE were searched, identifying 30 eligible studies (16 included in meta-analysis). Random-effects models were used to pool effect sizes and 95% confidence intervals comparing microstate parameters between AD, MCI, and healthy controls. RESULTS: Sixteen studies were included in the meta-analysis. In AD vs controls, microstate A duration (g = 0.41, 95% CI [0.10, 0.72]) and microstate B duration (g = 0.48, 95% CI [0.23, 0.73]) were significantly increased. In MCI vs controls, microstate D duration was significantly decreased (g = -0.26, 95% CI [-0.48, -0.04]) and microstate A occurrence rate was increased (g = 0.40, 95% CI [0.07, 0.74]), while microstate A and B duration were not significantly different. Heterogeneity was substantial for several outcomes. CONCLUSION: Pooled evidence suggests prolonged microstate A/B duration as the most reproducible alteration in AD, with reduced microstate D duration emerging as a modest finding in MCI. However, substantial heterogeneity and possible small-study effects indicate that current evidence is best interpreted as hypothesis-generating pending standardized, longitudinal, and multimodal studies. SIGNIFICANCE: EEG microstate analysis may provide complementary information about large-scale network dysfunction in MCI and AD, but methodological limitations currently constrain clinical biomarker interpretation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.